KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Histopathologic growth patterns as prognostic factor for survival in patients with colorectal liver metastases. PMID 41686533 · Radiol Oncol · 2026-Mar-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE Trial. PMID 41609798 · JAMA Oncol · 2026-Mar-01 This is a secondary analysis of cancer outcomes from the ASPREE trial, which was primarily a cardiovascular prevention trial in older adults. While randomized and drug-interventional (aspirin), it is not a primary report of a Phase III/IIIb or Phase II/III oncology trial, and the reported endpoints are secondary analyses of cancer incidence and mortality, not a primary/key secondary efficacy endpoint for an anticancer drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age. PMID 41274280 · Inflamm Bowel Dis · 2026-Mar-01 Study is not an oncology trial; it evaluates a drug (ozanimod) for ulcerative colitis (inflammatory bowel disease). While it is a Phase III randomized trial with a drug intervention and original results, it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and focuses on safety and clinical/mucosal efficacy rates, not Kaplan-Meier or time-to-event outcomes.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial. PMID 41270788 · J Natl Cancer Inst · 2026-Mar-01 The report is a randomized trial in human oncology with a drug intervention, but its primary analysis is focused on health-related quality of life, not a time-to-event efficacy endpoint. The time-to-event outcome (PFS) is mentioned in the background as part of the parent trial's results, but this specific report's methodology and results are dedicated to QoL assessment using patient-reported outcomes, not Kaplan-Meier or HR analysis. Therefore, it does not meet the time-to-event requirement.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Toxicities and Quality of Life following Observation or Radiation Therapy for Dupuytren's Disease: Three-Year Secondary Analysis Data From the Prevention Group of the International Dupuytren's Evaluation of Preventative or Adjuvant Radiation Therapy (DEPART) Randomized Trial. PMID 41027544 · Int J Radiat Oncol Biol Phys · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Fecal Immunochemical Test Completion by Instruction Type: A Randomized Clinical Trial Comparing Quick Response Code-Linked Video to Pictorial Instructions. PMID 40622392 · Am J Gastroenterol · 2026-Mar-01 The record describes a randomized quality improvement study comparing instruction methods for fecal immunochemical test (FIT) completion in colorectal cancer screening. While oncology and human criteria are met, and it is randomized, it lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR). The study is also not Phase III or II/III. Thus, it does not meet all eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Role of Preoperative Tapentadol in Reduction of Peri-operative Analgesics Requirements After Breast Conservative Surgery in Cancer Patients: A Randomized Controlled Trial. PMID 42394994 · J Cancer Allied Spec · 2026-Mar The study is a randomized, controlled trial involving a drug in an oncology (breast cancer) population, but it is an analgesia/safety study focused on perioperative pain management, not an efficacy trial for a cancer treatment with a time-to-event endpoint. Furthermore, the trial phase is not specified, so it cannot be confirmed as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol. PMID 42022357 · Precis Radiat Oncol · 2026-Mar 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113). PMID 41994030 · ESMO Gastrointest Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Tumor-Targeted IL-12 (PDS01ADC) with Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Non-randomized Phase II Trial. PMID 41937811 · JCO Oncol Adv · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Diet and Physical Activity Interventions to Improve Outcomes in Colorectal Cancer Survivors: A Multicenter Randomized Controlled Trial in North Africa. PMID 41886719 · JCO Glob Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-Term Survival Outcomes of Concurrent Chemoradiotherapy for Postoperative High-Risk Salivary Gland Carcinomas. PMID 41878954 · Cancer Med · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Randomized Controlled Trial: Evaluating the Sleep, Cancer and Rest (SleepCaRe) Trial to Improve Health-Related Quality of Life in Women Undergoing Chemotherapy for Breast Cancer. PMID 41866301 · Psychooncology · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial. PMID 41853747 · ESMO Gastrointest Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study. PMID 41852303 · Cancer Med · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effects of Exercise on Cognitive Impairment in Patients Receiving Chemotherapy: A Multicenter Phase III Randomized Controlled Trial. PMID 41825129 · J Natl Compr Canc Netw · 2026-Mar The study is an eligible Phase III randomized trial with drug-containing context (chemotherapy), but it fails the time-to-event endpoint criterion. The primary outcomes are cognitive impairment and mental fatigue scores, which are continuous patient-reported outcomes, not time-to-event events (like survival or progression). No Kaplan-Meier curves, hazard ratios, or time-to-event endpoints are mentioned.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multicentre dosimetry audit in the European randomized phase III study of neoadjuvant chemoradiotherapy using proton versus photon radiotherapy in locally advanced oesophageal cancer. PMID 41810037 · Phys Imaging Radiat Oncol · 2026-Mar The record is an abstract for a dosimetry audit (technical quality assurance) within a randomized phase III oncology trial. While the parent trial (PROTECT) is oncologic, human, randomized, and phase III, this specific abstract reports only on radiation dose measurement verification, not on any clinical efficacy endpoint (e.g., OS, PFS). Furthermore, the intervention compared is proton versus photon radiotherapy (non-drug), and the abstract does not present the primary trial results. Therefore, it is ineligible.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Critique of phase II agents for non-small cell lung cancer: what is our clinical need and which agents have potential? PMID 41797519 · Expert Opin Investig Drugs · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor. PMID 41792865 · Clin Transl Sci · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial. PMID 41785896 · Lancet Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma. PMID 41785669 · ESMO Open · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A pragmatic phase II trial evaluating treatment strategies using immune checkpoint inhibitors for metastatic esophageal cancer patients with severe dysphagia. PMID 41783111 · ESMO Gastrointest Oncol · 2026-Mar The study is a Phase II trial (not Phase III/IIIb or Phase II/III), and its primary endpoint is a symptom-based rate (dysphagia relief), not a time-to-event efficacy endpoint. The abstract describes an ongoing trial without results, classifying it as a protocol report.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Overall Survival of Glioblastoma Patients Treated With a Combination of 7 Micronutrients: A Nutraceutical Trial. PMID 41760279 · Anticancer Res · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
HCC recurrence in liver transplants treated with hypothermic oxygenated machine perfusion: An international matched cohort study. PMID 41737541 · JHEP Rep · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sex- and Age-Stratified Outcomes of Colonoscopy Versus Faecal Immunochemical Testing: Post-Analysis of the COLONPREV Study. PMID 41715250 · United European Gastroenterol J · 2026-Mar The study is a randomized, human, oncology trial comparing two screening methods (colonoscopy vs. FIT) for colorectal cancer mortality and incidence. However, it lacks a drug intervention and does not explicitly report time-to-event (Kaplan-Meier, HR) analyses, and it is not a Phase III trial of a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial. PMID 41713442 · Lancet Glob Health · 2026-Mar The record describes a randomized trial of tobacco cessation interventions for people living with HIV. While it includes a pharmacotherapy arm (nicotine replacement therapy), it is not an oncology trial and does not have a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Randomized Phase II Trial of Hypo-fractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction Versus Standard- Fractionated IMRT, Concurrent With Carboplatin/Paclitaxel and Followed by Consolidation Durvalumab, for Subjects With Stage III Non-Small Cell Lung Cancer. PMID 41687334 · Clin Lung Cancer · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Health technology assessment reports for oncology medications in Canada from 2018 to 2025: methodological critiques on manufacturers' submissions and a comparison between manufacturers and Canada's Drug Agency (CDA) analyses. PMID 41680120 · Expert Rev Pharmacoecon Outcomes Res · 2026-Mar The record is a health technology assessment (HTA) methodology review, not an original report of a randomized trial's efficacy results. It does not contain primary time-to-event endpoint data from a trial.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Protective effect of pituitrin combined with norepinephrine on cardiopulmonary injury in patients with septic shock diagnosed by critical care ultrasound evaluation. PMID 41620916 · Pak J Pharm Sci · 2026-Mar The study is a randomized controlled trial evaluating a drug combination for septic shock, not for an oncological indication. It lacks the required time-to-event efficacy endpoint (e.g., OS, PFS) necessary for Kaplan-Meier digitization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Geriatric prehabilitation prior to surgery for kidney tumors: Study protocol for Pre-KiT - A randomized controlled trial. PMID 41592385 · J Geriatr Oncol · 2026-Mar 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Assessing the cost-effectiveness of two psychoeducational interventions for people with cancer and their caregivers: An economic evaluation of the multi-country DIAdIC trial. PMID 41577124 · Contemp Clin Trials · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia. PMID 41571767 · Leukemia · 2026-Mar The record describes an immunomodulatory sub-study or correlative analysis within a Phase III trial. It does not report primary or key secondary time-to-event efficacy endpoints (OS, PFS, etc.) but instead analyzes immune cell phenotypes and counts. Therefore, it is not an eligible report for KM/HR efficacy analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial. PMID 41570843 · Lancet Gastroenterol Hepatol · 2026-Mar The study is a randomized, open-label, endpoint-blinded trial of nutritional therapies for paediatric Crohn's disease. It is not an oncology trial, does not involve a drug intervention, and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial. PMID 41556856 · Gastroenterology · 2026-Mar The study is an oncology randomized trial with a time-to-event endpoint but lacks a drug intervention (comparing diagnostic modalities only) and does not explicitly confirm a Phase III/IIIb or II/III design.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Expanding access to cancer genetic care for cancer survivors: Rationale and design for a randomized controlled trial of a chatbot-based genetic education and testing. PMID 41554333 · Contemp Clin Trials · 2026-Mar This is a protocol for an ongoing randomized controlled trial. It is not a report of trial results. It lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR); the primary outcome is genetic testing completion (a binary endpoint). The intervention is a chatbot-based education/testing model, which is not a drug-containing intervention. The trial is not Phase III/IIIb or Phase II/III (phase is not specified but the protocol describes an early-phase efficacy trial). Therefore, it fails multiple key eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG). PMID 41539214 · Lung Cancer · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. PMID 41529226 · J Clin Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial. PMID 41511419 · Gastroenterology · 2026-Mar 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care. PMID 41502912 · Immunooncol Technol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Indocyanine green fluorescence-guided proximal margin identification in laparoscopic distal gastrectomy: a randomized clinical trial. PMID 41489800 · Gastric Cancer · 2026-Mar 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review. PMID 41482478 · Br J Haematol · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD). PMID 41423505 · Br J Cancer · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Innovative oncology trial designs: Time to act - A review with recommendations of the Cancer Drug Development Forum. PMID 41423143 · J Cancer Policy · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial. PMID 41422947 · J Thromb Haemost · 2026-Mar The study is a reanalysis of a randomized trial in cancer patients using a 'win ratio' composite endpoint, which does not meet the required time-to-event efficacy endpoint criteria (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Additionally, the trial phase is not explicitly confirmed as Phase III or IIIb.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study. PMID 41390254 · Clin Colorectal Cancer · 2026-Mar The record describes a Phase II prospective study (TRAVASTIN) with a randomized component for a secondary comparison. While it reports original OS data, the primary trial phase is not Phase III/IIIb or Phase II/III, which is a required criterion. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A comparative study of the repair of surgical defects of the hypopharynx with the pedicled thoracoacromial artery perforator and supraclavicular artery island flap. PMID 41390242 · Acta Otolaryngol · 2026-Mar The study is a randomized trial in human oncology patients but is ineligible because it lacks a drug intervention and a time-to-event efficacy endpoint, focusing instead on surgical reconstruction outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
RoLaCaRT-1: pilot randomised phase II study of robotic vs laparoscopic hemicolectomy for right colon cancer. PMID 41372621 · Surg Endosc · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Ivor Lewis minimally invasive oesophagectomy versus McKeown approach: short-term benefits and mid-term equivalence in a randomized trial for oesophageal squamous cell carcinoma. PMID 41345532 · Surg Endosc · 2026-Mar The record describes a randomized surgical trial (Ivor Lewis vs McKeown oesophagectomy) for esophageal squamous cell carcinoma. It meets criteria for oncology, human, randomized, time-to-event endpoint (PFS), and original result. However, it fails the key criterion of a drug-containing intervention, as the comparison is between two surgical techniques. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or II/III in the provided metadata (phase3: false). Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preoperative Short-Term Nutrition and Exercise Trial Program for Patients with Esophageal Cancer: A Randomized Clinical Trial: Thoracic Oncology. PMID 41335173 · Ann Surg Oncol · 2026-Mar The study is an original, randomized, oncology trial in humans but does not meet key eligibility criteria: it lacks a drug-containing intervention (intervention is nutrition and exercise prehabilitation), lacks a time-to-event efficacy endpoint (primary outcome is a continuous physiological measure, not OS/PFS/DFS/etc.), and does not appear to be a Phase III/IIIb or Phase II/III drug efficacy trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Effect of Modified Chitosan Medical Membrane on the Inflammation and Recurrence After Primary Pterygium Excision: A Prospective Randomized Clinical Study. PMID 41314274 · Am J Ophthalmol · 2026-Mar The study is a randomized trial with results, but it is not oncology (pterygium excision), does not involve a drug intervention (chitosan membrane is a device/material), and lacks a primary time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -